Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
- Conditions
- Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2004-03-31
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 24
- Registration Number
- NCT00003967
- Locations
- 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-03-26
- Last Posted Date
- 2020-08-17
- Lead Sponsor
- Yale University
- Target Recruit Count
- 25
- Registration Number
- NCT00002950
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer
- Conditions
- Lung Cancer
- Interventions
- Radiation: radiation therapy
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00002537
- Locations
- 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Conditions
- Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2004-02-26
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00014690
- Locations
- 🇺🇸
AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, United States
Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome
- Conditions
- LeukemiaMyelodysplastic Syndromes
- First Posted Date
- 2004-02-25
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT00005593
- Locations
- 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Cleveland, Ohio, United States
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
- Conditions
- Ovarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2004-02-25
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00005026
- Locations
- 🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer
- Conditions
- Fallopian Tube CancerOvarian Cancer
- First Posted Date
- 2004-02-03
- Last Posted Date
- 2015-12-23
- Lead Sponsor
- AGO Study Group
- Registration Number
- NCT00006454
- Locations
- 🇩🇪
Medizinische Klinik I, Dresden, Germany
🇩🇪Christian-Albrechts University of Kiel, Kiel, Germany
🇩🇪Zentralkrankenhaus, Bremen, Germany
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
- Conditions
- Plasma Cell NeoplasmMultiple Myeloma
- Interventions
- First Posted Date
- 2004-02-02
- Last Posted Date
- 2019-11-08
- Target Recruit Count
- 131
- Registration Number
- NCT00005792
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- University Health Network, Toronto
- Registration Number
- NCT00072267
- Locations
- 🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
🇨🇦Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00005962
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Hahnemann University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸CCOP - Columbus, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.